Table #2.
Multi-Center Phyllodes Tumor Distribution of National Comprehensive Cancer Network Criteria, Genetic Testing, and Mutations Identified, 2007–2017.
| OVERALL N = 550 | Benign N=379 (68.9%) | Borderline N=108 (19.6%) | Malignant N=58 (10.5%) | |
|---|---|---|---|---|
| Any Family History of Cancer * | 329 (59.8%) | 220 (58.0%) | 70 (64.8%) | 39 (67.2%) |
| ≥3 Family Members with Cancer † | 112 (34.0%) | 71 (32.3%) | 22 (31.4%) | 19 (48.7%) |
| Met Any NCCN Criteria for Genetic Referral ‡ | 102 (18.5%) | 70 (18.5%) | 18 (16.7%) | 14 (24.1%) |
| - Close relative with pancreatic ca§ | 17 (16.7%) | 9 (12.9%) | 3 (16.7%) | 5 (35.7%) |
| - Close relative with ovarian ca | 36 (35.3%) | 25 (35.7%) | 8 (44.4%) | 3 (21.4%) |
| - Close relative with male breast ca | 4 (3.9%) | 3 (4.3%) | 0 (0%) | 1 (7.1%) |
| - ≥3 close relatives with any cancer | 68 (66.7%) | 48 (68.6%) | 11 (61.1%) | 9 (64.3%) |
| Genetic Testing Performed | 34 (6.2%) | 14 (3.7%) | 7 (6.5%) | 13 (22.4%) |
| Type of Genetic Testing ¶ | ||||
| - TP53 only | 2 (5.9%) | 0 (0%) | 0 (0%) | 2 (15.4%) |
| - BRCA1 & BRCA2 only | 13 (38.2%) | 9 (64.3%) | 3 (42.9%) | 1 (7.7%) |
| - BRCA1, BRCA2, & TP53 only | 5 (14.7%) | 1 (7.1%) | 0 (0%) | 4 (30.8%) |
| - ≥5 Genes Tested | 10 (29.4%) | 2 (14.3%) | 3 (42.9%) | 5 (38.5%) |
| - ≥10 Genes Tested | 9 (26.5%) | 2 (14.3%) | 3 (42.9%) | 4 (30.8%) |
| - ≥15 Genes Tested | 6 (17.6%) | 1 (7.1%) | 1 (14.3%) | 4 (30.8%) |
| - ≥25 Genes Tested | 4 (11.8%) | 0 (0%) | 1 (14.3%) | 3 (23.1%) |
| - Included TP53 in any testing type | 17 (50.0%) | 2 (14.3%) | 3 (42.9%) | 12 (92.3%) |
| Gene Mutations Identified | 3 (8.8%) | 1 (7.1%) | 0 (0%) | 2 (15.4%) |
| - TP53 | 2 (5.9%) | 0 (0%) | 0 (0%) | 2 (15.4%) |
| - BRCA1 | 1 (2.9%) | 1 (7.1%) | 0 (0%) | 0 (0%) |
| - BRCA2 VUS** | 2 (5.9%) | 2 (14.3%) | 0 (0%) | 0 (0%) |
Including at least one 1st-, 2nd-, or 3rd-degree relative on either maternal or paternal side
Including ≥3 close relatives on maternal or ≥3 close relatives on paternal side, percentages out of those with any family history (N=329)
Percentages for all variables in this section are out of the number of patients who were eligible for genetic testing
Close relative as defined by NCCN, 1st-, 2nd-, or 3rd-degree relative
All percentages are out of the total that underwent testing in each group
One patient with benign phyllodes had both a BRCA1 mutation and a BRCA2 VUS
Data presented as N (%) unless otherwise specified. Percentages may not add up to 100 due to rounding or missing values.